Table 1.

Clinical correlations for patients with “high” or “low” systemic G-MDSCsa–G-MDSCs levels do not correlate with disease severity.

G-MDSC“High”“Low”P-value
N = 7N = 18
Age (y)
 <65280.66b
 >65510
Performance status (ECOG)
 03120.56c
 112
 234
Tumor type
 Ductal5110.67c
 Lobular24
 Other03
NHG
 1021.00c
 2410
 313
 Unknown23
Tumor size (T)
 T1570.65c
 T215
 T303
 T413
Node status (N)
 N+3130.17c
 N−44
 Unknown01
Adjuvant chemotherapy
 Yes290.41c
 No59
Adjuvant endocrine therapy
 Yes3150.07c
 No43
Breast cancer Subtyped
 ER+HER23150.16c
 HER2+(ER+/−)11
 TNBC (ERHER2)22
 Unknown10
Metastasis-free interval (y)
 0110.57c
 >0–303
 >3614
Number of metastatic sites
 0–26120.63c
 3–516
Metastatic site
 Lymph nodes versus not2/57/111.0c
 Lung versus not2/59/90.41c
 Liver versus not1/64/141.0c
 Bone versus not5/214/41.0c
 Visceral versus not4/312/60.67c
 Bone-only versus not1/64/141.0c
Number of CTCs
 ≥5391.0c
 <549
Peripheral neutrophil count
 Median (range)7.20 (4.00–12.20)4.00 (2.00–10.20)<0.05e,f
  • a The highest level of healthy control G-MDSCs were set as normal range value (10.5% of PBMCs). “Low” G-MDSCs were patients with G-MDSCs below and up to normal range (≤10.5%). “High” G-MDSCs were patients with G-MDSCs levels above the healthy control normal range (>10.5%).

  • b P-value from Pearson’s chi-squared test.

  • c P-value from Fisher’s Exact Test.

  • d Breast cancer subtype was primarily derived from immunohistochemical staining of the metastasis. If no information was available from the metastasis, the subtype was derived by staining of the primary tumor.

  • e P-value from Mann Whitney test.

  • f P < 0.05.